Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory.

Archive ouverte

Benchenane, Karim | Castel, Hervé | Boulouard, Michel | Bluthé, Rosemarie | Fernandez-Monreal, Monica | Roussel, Benoit D | Lopez-Atalaya, José P | Butt-Gueulle, Sabrina | Agin, Véronique | Maubert, Eric | Dantzer, Robert | Touzani, Omar | Dauphin, François | Vivien, Denis | Ali, Carine

Edité par CCSD ; Company of Biologists -

International audience. Fine-tuning of NMDA glutamatergic receptor signalling strategically controls crucial brain functions. This process depends on several ligands and modulators, one of which unexpectedly includes the serine protease tissue-type plasminogen activator (tPA). In vitro, tPA increases NMDA-receptor-mediated calcium influx by interacting with, and then cleaving, the NR1 subunit within its N-terminal domain. Owing to lack of in vivo evidence of the relevance and contribution of this mechanism in physiological and pathological brain processes, active immunisation was developed here in mice, to allow transient and specific prevention of the interaction of tPA with the NR1 subunit. Immunisation significantly reduced the severity of ischemic and excitotoxic insults in the mouse brain. Cognitive function was altered in some, but not all behavioural tasks affected in tPA-deficient mice. Our data demonstrate that in vivo, tPA controls neurotoxicity and the encoding of novel spatial experiences by binding to and cleaving the NMDA receptor NR1 subunit. Interesting therapeutic possibilities for several brain pathologies that involve excitotoxicity may now be envisaged.

Consulter en ligne

Suggestions

Du même auteur

Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact.

Archive ouverte | Roussel, Benoit, D | CCSD

International audience. Recombinant tissue-type plasminogen activator (tPA) is the fibrinolytic drug of choice to treat stroke patients. However, a growing body of evidence indicates that besides its beneficial thro...

Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor–related protein-mediated transcytosis

Archive ouverte | Benchenane, Karim | CCSD

International audience. Background—Accumulating evidence demonstrates a critical involvement of tissue-type plasminogen activator (tPA) in pathological and physiological brain conditions. Determining whether and how...

Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process

Archive ouverte | Benchenane, Karim | CCSD

International audience. Background and Purpose—Despite uncontroversial benefit from its thrombolytic activity, the documented neurotoxic effect of tissue plasminogen activator (tPA) raises an important issue: the cu...

Chargement des enrichissements...